Multicenter Registry for the Optimal Antithrombotic Therapy in the Patients with Arial Fibrillation Undergoing Percutaneous Coronary Intervention Study
Not Applicable
- Conditions
- Atrial fibrillation Coronary artery disease
- Registration Number
- JPRN-UMIN000015531
- Lead Sponsor
- Department of Cardiovascular Medicine, Kitasato University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have already been implanted other DES Patiens with acute myocardial infarction Patients judged by the treating physician to be unsuitable as study subjects
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie antithrombotic efficacy in AF patients undergoing PCI with dual antiplatelet therapy and anticoagulants?
How do NOACs compare to warfarin in managing stroke risk for AF patients with coronary artery disease during PCI procedures?
Which biomarkers predict bleeding risk or thrombotic event outcomes in AF patients receiving combined antithrombotic regimens post-PCI?
What adverse event profiles are associated with triple therapy (antiplatelet + anticoagulant) in atrial fibrillation and CAD patients per JPRN-UMIN000015531?
What combination strategies of antiplatelet agents and anticoagulants show optimal safety in AF patients with stable versus unstable coronary artery disease?